(News Bulletin 247) – Bayer today announced positive two-year (96-week) results from a trial of aflibercept 8 mg in patients with neovascular (wet) age-related macular degeneration ( AMD).
Data Reinforces Lasting Vision Gains with Unprecedented Extended Treatment Intervals of Aflibercept 8mg Reaching Up to 24 Weeks with Effectiveness and Safety Comparable to Current Standard of Care Eylea™ (Aflibercept 2mg) with Intervals fixed for 8 weeks.
According to the laboratory, ‘the durability results are impressive and demonstrate the long-lasting efficacy of treatment with aflibercept 8 mg throughout the second year of treatment’.
“I am delighted with the two-year results of the trial as they offer the potential to reduce the treatment burden for the vast majority of patients with neovascular age-related macular degeneration in the future,” said Dr. Christian Rommel, director of R&D at Bayer.
Bayer has submitted regulatory applications for aflibercept 8 mg in Europe and other markets. Aflibercept 8mg is not currently approved in any country.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
